Dr. Colombel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 E 98th St
New York, NY 10029Phone+1 212-241-4299Fax+1 212-426-5099
Education & Training
- OtherClass of 1984
Certifications & Licensure
- NY State Medical License 2013 - 2025
Publications & Presentations
PubMed
- Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis.Joan Shang, Diane Marie Del Valle, Graham J Britton, K R Mead, Urvija Rajpal
The Journal of Experimental Medicine. 2025-01-06 - A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.Silvio Danese, Michael E Rothenberg, Jeremy J Lim, Han Ting Ding, Jacqueline M McBride
Clinical Gastroenterology and Hepatology. 2024-12-16 - Coincidence of antibodies against Hwp1 and ASCA, two distinct molecular targets of, reinforces the link between this fungal species and coeliac disease.Boualem Sendid, Christopher Cao, Jean-Frederic Colombel, Daniel Poulain
Virulence. 2024-12-01
Press Mentions
- Growing up with a Dog Might Protect Against Crohn's DiseaseMay 26th, 2022
- Vedolizumab Doesn’t Increase Risk of C Diff in Ulcerative ColitisDecember 28th, 2021
- Very Few Patients with IBD Get Early VedolizumabDecember 28th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: